EGFR and gastric mucosal hypertrophy: Importantly, treatment of Ménétrier’s disease patients with antibodies against the EGFR led to amelioration of the foveolar hyperplasia, with decreases in phosphorylation of EGFR and ERK1/2, as well as return of gastric parietal cells.9